Кардиоренальные синдромы


Ж.Д. Кобалава, М.А. Ефремовцева, С.В. Виллевальде

Кафедра пропедевтики внутренних болезней РУДН, Москва
Описаны патофизиологические механизмы, подходы к диагностике и лечению клинических вариантов кардиоренальных синдромов.

Литература


1. Lindner A., Charra B., Sherrard D.J., Scribner B.H: Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med. 1974; 290: 697–701.
2. Foley R.N., Parfrey P.S., Sarnak M.J. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998;32: 112–119.
3. Prevalence of low glomerular filtration rate in nondiabetic Americans: Third National Health and Nutrition Examination Survey (NHANES III). J Am Soc Nephrol. 2002; 13(5): 1338–1349.
4. Sarnak M.J., Levey A.S., Schoolwerth A.C. et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003;108:2154–2169.
5. Heywood J.T. The cardiorenal syndrome: lessons from the ADHERE database and treatment options. Heart Fail Rev. 2004;9:195–201.
6. Chadban S.J., Briganti E.M., Kerr P.G., Dunstan D.W., Welborn T.A., Zimmet P.Z., Atkins R.C.: Prevalence of kidney damage in Australian adults: The AusDiab kidney study. J Am Soc Nephrol. 2005; 14[Suppl]: 131–138.
7. Foley R., Murray A., Li S. et al. Chronic Kidney Disease and the Risk for Cardiovascular Disease, Renal Replacement, and Death in the United States Medicare Population, 1998 to 1999. J Am Soc Nephrol. 2005; 16: 489–495.
8. McCullough P.A., Li S, Jurkovitz C.T. et al. CKD and cardiovascular disease in screened high-risk volunteer and general populations: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. Am J Kidney Dis. 2008; 51 (4 Suppl 2): 38–45.
9. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 suppl 1):S1–S266.
10. Моисеев В.С., Кобалава Ж.Д. Кардиоренальный синдром (почечный фактор и повышение риска сердечно-сосудистых заболеваний). Клиническая фармакология и терапия. 2002;11(3):16–18.
11. Мухин Н.А., Моисеев В.С. Кардиоренальные соотношения и риск сердечно-сосудистых заболеваний. Вестник РАМН. 2003;11:50–55.
12. Мухин Н.А., Моисеев В.С., Кобалава Ж.Д. и др. Кардиоренальные взаимодействия: клиническое значение и роль в патогенезе заболеваний сердечно-сосудистой системы и почек. Тер архив. 2004;6:39–46.
13. Palevsky PM: Epidemiology of acute renal failure: the tip of the iceberg. Clin J Am Soc Nephrol. 2006; 1: 6–7.
14. Mehta R.L., Kellum J.A., Shah S.V. et al. Acute Kidney Injury Network (AKIN): report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007; 11:R31.
15. Bellomo R., Ronco C., Kellum J.A. et al. and the ADQI workgroup: Acute renal failure – definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004; 8:R204-R212.
16. Ledoux P. Cardiorenal syndrome. Avenir Med. 1951; 48(8):149–153.
17. Palaniappan L, Carnethon M, Formann SP. Association between microalbuminuria and the metabolic syndrome: NHANES III. Am J Hypertens. 2003; 16(11):952–958.
18. Silverberg D.S. Outcomes of anaemia management in renal insufficiency and cardiac disease. Nephrol Dial Transplant. 2003; 18 (suppl 2): ii7–ii12.
19. Dzau V. The cardiovascular continuum and renin-angiotensin-aldosterone system blockade. J Hypertens. 2005;23(suppl 1):S9–S17.
20. The Task Force for the Management of Arterial Hypertension of theEuropean Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) EНJ 2007; 28: 1462–1536.
21. Диагностика и лечение артериальной гипертензии. В: Национальные клинические рекомендации. Сборник / Под ред. Р.Г. Оганова. 3-е изд. М.: Силицея-Полиграф. 2010. 464–500. 22. Функциональное состояние почек и прогнозирование сердечно-сосудистого риска. В: Национальные клинические рекомендации. Сборник / Под ред. Р.Г. Оганова.-3-е изд. М.: Силицея-Полиграф. 2010. 558–584.
23. Liang K.V., Williams A.W., Greene E.L., Redfield M.M. Acute decompensated heart failure and the cardiorenal syndrome. Crit Care Med. 2008;36:S75–88.
24. Ronco C., McCullough P., Anker S. et al.Cardio-renal syndromes: report from the consensus conference of the Acute Dialysis Quality Initiative. Eur Heart J 2010; 31:703–711.
25. Latchamsetty R., Fang J., Kline-Rogers E. et al. Prognostic Value of Transient and Sustained Increase in In-Hospital Creatinine on Outcomes of Patients Admitted With Acute Coronary Syndrome. Am J Cardiol. 2007;99(7):939–942.
26. Jose P., Skali H., Anavekar N. et al. Increase in Creatinine and Cardiovascular Risk in Patients with Systolic Dysfunction after Myocardial Infarction. J Am Soc Nephrol. 2006;17: 2886–2891.
27. Berl T., Henrich W. Kidney-heart interactions: epidemiology, pathogenesis, and treatment. Clin J Am Soc Nephrol. 2006;1:8–18.
28. Gottlieb S.S., Abraham W., Butler J. et al. The prognostic importance of different definitions of worsening renal function in congestive heart failure. J Card Fail. 2002;8:136–141.
29. Krumholz H.M., Chen Y.T., Vaccarin. V. et al. Correlates and impact on outcomes of worsening renal function in patients ≥ 65 years of age with heart failure. Am J Card. 2000;85:1110–1113.
30. Cowie M.R., Komajda M., Murray-Thomas T. et al. Prevalence and impact of worsening renal function in patients hospitalized with decompensated heart failure: results of the prospective outcomes study in heart failure (POSH). EHJ 2006;27:1216–22.
31. Smith G.L., Vaccarino V., Kosiborod M. et al. Worsening renal function: What is a clinically meaningful change in creatinine during hospitalization with heart failure? J Card Fail. 2003;9:13–25.
32. Ronco C., Bellomo R., McCullough P.A. Cardiorenal Syndromes in Critical Care. Contrib Nephrol. 2010; Basel, Karger, 2010, vol 165.
33. Adams K.F., Fonarow G.C., Emerman C.L. et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the acute decompensated heart failure national registry (ADHERE). Am Heart J 2005;149:209–216.
34. Fonarow G.C., Stough W.G., Abraham W.T. et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF registry. J Am Coll Cardiol 2007;50:768–777.
35. Jose P., Skali H., Anavekar N. et al. Increase in creatinine and cardiovascular risk in patients with systolic dysfunction after myocardial infarction. J Am Soc Nephrol 2006;17:2886–2891.
36. Goldberg A., Hammerman H., Petcherski S. et al. Inhospital and 1-year mortality of patients who develop worsening renal function following acute ST-elevation myocardial infarction. Am Heart J 2005;150:330–307.
37. Costanzo M.R., Guglin M.E., Saltzberg M.T., et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 2007 13;49:675–683.
38. Tessone A., Gottlieb S., Barbash I.M. et al. Underuse of standard care and outcome of patients with acute myocardial infarction and chronic renal insufficiency. Cardiology 2007;108:193–199.
39. Ahmed A., Rich M.W., Sanders P.W. et al. Chronic Kidney Disease Associated Mortality in Diastolic Versus Systolic Heart Failure: A Propensity Matched Study. Am J Cardiol 2007;99:393–398.
40. Campbell R.C., Sui S., Filippatos G. et al. Association of chronic kidney disease with outcomes in chronic heart failure: a propensity-matched study. Nephrol Dial Transplant 2009; 24:186–193.
41. Forman D.E., Butler J., Wang Y. et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol 2004;43:61–67.
42. Hillege H.L., Nitsch D., Pfeffer M.A. et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 2006;113:671–678.
43. Dimopoulos K., Diller G.P., Koltsida E. et al. Prevalence, Predictors, and Prognostic Value of Renal Dysfunction in Adults With Congenital Heart Disease. Circulation. 2008;117:2320–2328.
44. Bhatia R.S., Tu J.V., Lee D.S. et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006; 355:260–269.
45. Despres J.-P. Abdominal obesity: the most prevalent cause of the metabolic syndrome and related cardiometabolic risk. Eur Heart J. 2006; 8 (suppl. B): B4–B12.
46. Lea J.P., Greene E.L., Nicholas S.B. et al. Cardiorenal metabolic syndrome in the african diaspora: rationale for including chronic kidney disease in the metabolic syndrome definition. Ethn Dis.2009;19(Suppl 2): 11–14.
47. Roghi A., Savonitto S., Cavallini C. et al. Impact of acute renal failure following percutaneous coronary intervention on long-term mortality. J Cardiovasc Med 2008;9:375–381.
48. Lassnigg A., Schmid E.R., Hiesmayr M. et al. Impact of minimal increases in serum creatinine on outcome in patients after cardiothoracic surgery: do we have to revise current definitions of acute renal failure? Crit Care Med 2008;36:1129–1137.
49. Hirsch A.T., Haskal Z.J., Hertzer N.R. et al. ACC/AHA guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society for Vascular Medicine and Biology, and the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease). J Am Coll Cardiol 2006;47:e1–192.
50. Coresh1 J., Stevens L., Levey A. Chronic kidney disease is common: What do we do next? Nephrol Dial Transplant. 2008; 23(8): 1122–1125.
51. McClellan W. The epidemic of renal disease – what drives it and what can be done? Nephrol Dial Transplant. 2006; 21(6): 1461–1464.
52. Levin A., Foley R.N. Cardiovascular disease in chronic renal insufficiency. Am J Kidney Dis 2000;36:S24–30.
53. Jie K.E., Verhaar M.C., Cramer M.J. et al. Erythropoietin and the cardiorenal syndrome: Cellular mechanisms on the cardiorenal connectors. Am J Physiol Renal Physiol 2006;291:F932–44.
54. Palazzuoli A., Silverberg D.S., Iovine F. et al. Effects of beta-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome. Am Heart J 2007;154:645.e9–15.
55. House A.A., Haapio M., Lassus J. et al. Therapeutic strategies for heart failure in cardiorenal syndromes. Am J Kidney Dis 2010; 56:759–773.
56. Roy P., Bouchard J., Amyot R., Madore F. Prescription patterns of pharmacological agents for left ventricular systolic dysfunction among hemodialysis patients. Am J Kidney Dis 2006;48:645–51.
57. Ko D.T., Juurlink D.N., Mamdani M.M. et al. Appropriateness of spironolactone prescribing in heart failure patients: a populationbased study. J Card Fail 2006;12:205–210.
58. Bagshaw S.M., Lapinsky S., Dial S. et al. Acute kidney injury in septic shock: clinical outcomes and impact of duration of hypotension prior to initiation of antimicrobial therapy. Intensive Care Med 2009;35:871–881.
59. Oppert M., Engel C., Brunkhorst F.M. et al. Acute renal failure in patients with severe sepsis and septic shock – a significant independent risk factor for mortality: results from the German Prevalence Study. Nephrol Dial Transplant 2008;23:904–909.
60. Ammann P., Maggiorini M., Bertel O. et al. Troponin as a risk factor for mortality in critically ill patients without acute coronary syndromes. J Am Coll Cardiol 2003;41: 2004–2009.
61. Bongartz L.G., Cramer M.J., Doevendans P.A. et al. The severe cardiorenal syndrome: ‘Guyton revisited.’ Eur Heart J 2005;26:11–17.
62. Brewster U.C., Setaro J.F., Perazella M.A. The renin-angiotensinaldosterone system: cardiorenal effects and implications for renal and cardiovascular disease states. Am J Med Sci.2003;326:15–24.
63. Silverberg D.S., Wexler D., Blum M. et al. The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol. 2000;35:1737–1744.
64. Levin A., Thompson C.R., Ethier J. et al. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis. 1999;34:125–134.
65. Ronco C., Cruz D.N. Biomarkers in cardio-renal syndromes (Rassegna). Altri Contributi LigandAssay 14 (4) 2009: 340–349.
66. Austin W.J., Bhalla V., Hernandez-Arce I. et al. Correlation and prognostic utility of B-type natriuretic peptide and its aminoterminal fragment in patients with chronic kidney disease. Am J Clin Pathol 2006;126:506–512.
67. Needham D.M., Shufelt K.A., Tomlinson G. et al. Troponin I and T levels in renal failure patients without acute coronary syndrome: a systematic review of the literature. Can J Cardiol 2004; 20: 1212–1218.
68. Abbas N.A., Jhon R.I., Webb M.C. et al. Cardiac troponins and renal function in nondialysis patients with chronic kidney disease. Clin Chem 2005; 51:2059–2066.
69. Roberts M.A., MacMillan N., Hare D.L. et al. Cardiac troponin levels in asymptomatic patients on the renal transplant waiting list. Nephrology (Carlton) 2006; 11: 471–476.
70. Braunwald E. Biomarkers in heart failure. N Engl J Med 2008;358: 2148–59. 71. Han W.K., Bonventre J.V. Biologic markers for the early detection of acute kidney injury. Curr Opin Crit Care 2004;10:476–482.
72. Ronco C. NGAL: an emerging biomarker of acute kidney injury. Int J Artif Organs 2008;31:199–200.
73. VandeVoorde R.G., Katlman T.I., Ma Q. et al. Serum NGAL and cystatin C as predictive biomarkers for acute kidney injury. J Am Soc Nephrol 2006;17:404A.
74. Han W.K., Bailly V., Abichandani R., Thadhani R., Bonventre J.V. Kidney injury molecule-1 (KIM-1): A novel biomarker for human renal proximal tubule injury. Kidney Int 2002;62:237–244.
75. Parikh C.R., Devarajan P. New biomarkers of acute kidney injury. Crit Care Med 2008; 36(4 Suppl): 159–165.
76. Price R.G. The role of NAG (N-acetyl-beta-D-glucosaminidase) in the diagnosis of kidney disease including the monitoring of nephrotoxicity. Clin Nephrol 1992; 38 (Suppl 1): 14–19.
77. Tonelli M., Wiebe N., Culleton B. et al. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 2006;17: 2034–2047.


Об авторах / Для корреспонденции


Кобалава Ж.Д. – профессор кафедры пропедевтики внутренних болезней РУДН, д.м.н.;
Ефремовцева М.А. – доцент кафедры пропедевтики внутренних болезней РУДН, к.м.н.
E-mail: marinaef56@mail.ru;
Виллевальде С.В. – доцент кафедры пропедевтики внутренних болезней РУДН, д.м.н.


Похожие статьи


Бионика Медиа